Breast cancer is a heterogeneous, most frequent disease in women. All patients with breast cancer may develop progression or recurrence of the disease, and thus they need an effective lifelong follow-up (Lumachi et al., 2001). Breast cancer recurrence is a significant problem for clinicians. Even patients with early stage of the disease (stage I–II) have a recurrence rate of ∼ 30%, and local recurrences after conserving therapy have been reported from 6% to 12% at 5 and 10 years, respectively (Temple et al., 1999). In spite of advances in the diagnosis and therapy achieved over the past decade, a share of patients with breast cancer still develop relapse and metastases, from which they will ultimately die (Cheung et al., 2000).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Al-azawi, D., Kelly, G., Myers, E., McDermott, E.W., Hill, A.D.K., Duffy, M.J., and 'Higgins, N. 2006. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 6: 220–226
Bartsch, R., Wenzel, C., Pluschnig, U., Hussian, D., Sevelda, U., Altojai, G., Locker, G.J., Mader, R., Zielinski, C.C., and Steger, G.G. 2006. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 6: 81–87
Cheung, K.L., Graves, C.R.L., and Robertson, J.F.R. 2000. Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 26: 91–102
Duffy, M.J. 2006. Serum tumor markers in breast cancer: are they of clinical value ? Clin. Chem. 52: 345–351
Given, M., Scott, M., Mc Grath, J.P., and Given, H. 2000. The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 9: 277–280
Haidopoulos, D., Konstadoulakis, M.M., Antonakis, P.T., Alexiou, D.G., Manouras, A.M., Katsaragakis, S.M., and Androulakis, G.F. 2000. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Eur. J. Surg. Oncol. 26: 742–746
Keshaviah, A.S., Dellapasqua, S., Rotmensz, N., Lindtner, J., Crivellari, D., Collins, J., Colleoni, M . , Thurlimann, B., Mendiola, C., Aebi, S., Price, K.N., Pagani, O., Simoncini, E., Castiglione Gertsch, M., Gelber, R., Coates, A.S., and Goldhirsch, A. 2007. CA 15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann. Oncol. 18: 701–708
Khatcheressian, J.L., Wolff, A.C., Smith, T.J., Grunfeld, E., Muss, H.B., Vogel, V.G., Halberg, F., Somerfield, M.R., and Davidson, N.E. 2006. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol. 24: 5091–5097
Li, J., Zhao, J., Yu, X., Lange, J., Kuerer, H., Krishnamurthy, S., Schilling, E., Khan, S.A., Sukumar, S., and Chan, D.W. 2005. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 11: 8312–8320
Lumachi, F., and Basso, S.M.M. 2004. Serum tumor markers in patients with breast cancer. Expert Rev, Anticancer Ther. 4: 921–931
Lumachi, F., Brandes, A.A., Ermani, M., Bruno, G., and Boccagni, P. 2000. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res. 20: 4751–4755
Lumachi, F., Ermani, M., Brandes, A.A., Basso, S.M., Basso, U., and Boccagni, P. 2001. Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res. 21: 4105–4108
Lumachi, F., Basso, S.M.M., Brandes, A.A., Pagano, D., and Ermani, M. 2004. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 24: 3221–3224
McIntosh, M.W., Urban, N., and Karlan, B. 2002. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol. Biomarkers Prev. 11: 159–166
Molina, R., Barak, V. , van Dalen, A., Duffy, M.J., Einarsson, R., Gion, M., Hoike, H., Lamerz, R., Nap, M., Sölétormos, G., and Stieber, P. 2005. Tumor markers in breast cancer-European Group on tumor markers recommendation. Tumor Biol. 26: 281–293. Nicolini, A., Carpi, A., Ferrari, P., Anselmi, L., Spinelli, C., Conte, M., and Miccoli, P. 2000. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer 83: 1412–1417
Nicolini, A., Carpi, A., Ferrari, P., Anselmi, L., Spinelli, C., Conte, M., and Miccoli, P. 2000. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer 83: 1412–1417
Stearns, V. , Yamauchi, H., and Hayes, D.F. 1998. Circulating tumor markers in breast cancer:accepted utilities and novel prospects. Breast Cancer Res. Treat. 52: 239–259
Temple, L.K., Wang, E.E., and McLeod, R.S. 1999. Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ 161:1001–1008
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Lumachi, F., Basso, S.M.M., Basso, U. (2008). Breast Cancer Recurrence: Role of Serum Tumor Markers CEA and CA 15-3. In: Hayat, M.A. (eds) Methods of Cancer Diagnosis, Therapy and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8369-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4020-8369-3_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-8368-6
Online ISBN: 978-1-4020-8369-3
eBook Packages: MedicineMedicine (R0)